 Hi, my name is Isabelle. I'm just starting my second year at Fondueville in the Chocolate Neurology Group. And my research relates to T-cell responses to cells going to innovative classes for their measurement. So we're interested in T-cell responses to cells going to be induced either by the vaccine or by the virus itself, because T-cells play a really important role in control of viral infection. TDA T-cells have role in direct killing of infected cells and CD4 T-cells provide help to other immune cells. So for example, we've had many antibodies without your CD4 T-cells telling your B-cells what to do. So for the first part of my data, I've been investigating correlates of protection against COVID-19 breakthrough infection. That is infection with SARS-CoV-2 after having received two doses for SARS-CoV-2 vaccines. So for this, I've been using samples from Pitch, which is a national cohort study of healthcare workers. Many of them were enrolled before their first vaccine dose and have been followed up to after their third vaccine dose. And a number of them have experienced breakthrough infection between their second and third doses, of which Delta was the dominant SARS-CoV-2 variant in the UK. So I've been using samples from the dose two plus one month time point, which roughly corresponds with the peak immune response after second vaccination to identify the breakthrough cases and match controls. And then in these two groups to compare their antibody responses, their memory B-cell responses and their T-cell responses to attempt to identify cross-protection against infection. We've particularly interested in T-cell responses in this context, because T-cell responses are often not studied at scale. For example, they weren't investigated in many of the phase three trials for COVID-19 vaccines. And part of the reason for this is because current T-cell assay is a complex time consuming and resource intensive. So for example, which is gold standard in our lab involves isolation and PBMCs, which is technically challenging, the private preservation of cells before simulation, which can introduce some variability, and specialist equipment pertaining to read-out. So for the second part of my detail, I'll be building on previous work in the lab to develop scalable T-cell assays that are quantitative and also practical for using the collaborating sites such as Thailand. I do need to be able to use whole blood and standard laboratory equipment for using a read-out.